叶可素受体对抗剂和多炎的好色素粒症:来自FAERS,JADER,CVAR数据库的不相称性分析,与网络药理学集成
Cuilv Liang1, Pingping Zhuo2, Yin Zhang1
1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
PloS one
|March 9, 2026
概括
胰岛素受体对抗剂 (LTRAs) 与患有多炎 (EGPA) 带来的eosinophilic granulomatosis的风险增加有关. 这项研究确定了这种不良药物反应背后的潜在遗传机制,有助于临床意识.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 莱克三烯受体对抗剂 (LTRA) 和与多炎 (EGPA) 相关的异osinophilic 颗粒炎之间的关联一直存在争议.
- 之前的研究已经给出了关于在使用LTRA后EGPA的风险的两极分化结果.
- 了解LTRAs诱导的EGPA的潜在毒理机制对于患者的安全至关重要.
研究的目的:
- 为了调查与白血受体抗剂 (LTRA) 使用相关的EGPA风险.
- 探索潜在的毒理机制和涉及LTRAs诱导EGPA的遗传因素.
- 为临床医生提供证据,说明在使用LTRA时EGPA的风险.
主要方法:
- 从FAERS,JADER和CVAR数据库中获取不良事件报告的现实世界药监测研究.
- 包括ROR,PRR,IC和EBGM在内的统计分析,以评估LTRA和EGPA之间的关联.
- 韦布尔形状参数 (WSP) 试验用于时间到发病分析和网络药理学用于机制探索.
主要成果:
- 在多个数据库中,LTRAs (montelukast,zafirlukast,pranlukast) 与EGPA显著相关.
- 蒙特卢卡斯特仍然与EGPA显著相关,即使排除了皮质类固醇的使用.
- 网络药理学确定了可能调解LTRAs诱导的EGPA的关键基因 (SRC,PTGS2,EDN1,HMOX1,KDR,OCLN).
结论:
- 胰岛素受体对抗剂 (LTRAs) 与聚炎 (EGPA) 带来的埃索诺菲尔粒状瘤病的风险增加有关.
- 这项研究提供了对LTRAs诱导EGPA的基因和分子机制的初步见解.
- 临床医生应警患者的EGPA症状处方LTRAs.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
01:26Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K